1. Home
  2. PHGE vs SYNX Comparison

PHGE vs SYNX Comparison

Compare PHGE & SYNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BiomX Inc. COmmon Stock

PHGE

BiomX Inc. COmmon Stock

HOLD

Current Price

$0.70

Market Cap

7.5M

Sector

Health Care

ML Signal

HOLD

Logo Silynxcom Ltd.

SYNX

Silynxcom Ltd.

HOLD

Current Price

$1.25

Market Cap

7.3M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
PHGE
SYNX
Founded
2015
2005
Country
United States
Israel
Employees
57
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.5M
7.3M
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
PHGE
SYNX
Price
$0.70
$1.25
Analyst Decision
Hold
Analyst Count
1
0
Target Price
N/A
N/A
AVG Volume (30 Days)
299.8K
96.8K
Earning Date
05-15-2026
05-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$32.35
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.25
$0.73
52 Week High
$8.50
$2.15

Technical Indicators

Market Signals
Indicator
PHGE
SYNX
Relative Strength Index (RSI) 22.26 51.32
Support Level $0.43 $0.93
Resistance Level $2.35 $1.34
Average True Range (ATR) 0.16 0.09
MACD 0.03 0.00
Stochastic Oscillator 4.71 42.42

Price Performance

Historical Comparison
PHGE
SYNX

About PHGE BiomX Inc. COmmon Stock

BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).

About SYNX Silynxcom Ltd.

Silynxcom Ltd is engaged in developing, manufacturing, marketing, and selling ruggedized Personal Headset Devices as well as other communications accessories, all of which have been battlefield-tested and combat proved. It specializes in developing the In-Ear Headset device, a subsegment of the Personal Headset Device market. The In-Ear Headset device is used in both training and operations by the military, law enforcement, and disaster recovery industry professionals. It also develops, markets, and sell push-to-talk devices, communication controllers, and communication device cables and connectors.

Share on Social Networks: